Provided by Tiger Fintech (Singapore) Pte. Ltd.

Beam Therapeutics, Inc.

17.41
+0.16000.93%
Pre-market: 17.980.5700+3.27%07:12 EDT
Volume:2.38M
Turnover:42.57M
Market Cap:1.70B
PE:-3.80
High:18.75
Open:17.40
Low:17.37
Close:17.25
Loading ...

Beam Therapeutics Is Maintained at Equal-Weight by Barclays

Dow Jones
·
07 May

Beam Therapeutics Inc : Bofa Global Research Raises Price Objective to $43 From $42

THOMSON REUTERS
·
07 May

Barclays Remains a Hold on Beam Therapeutics (BEAM)

TIPRANKS
·
07 May

24H|Crypto Shares Gain; Canaan up 10%; Riot Platforms up 5%; Medical AI Stocks Rise; RXRX up 4%; Gold Shares Fall

Tiger Newspress
·
07 May

Sector Update: Health Care Stocks Fall Late Afternoon

MT Newswires Live
·
07 May

Sector Update: Health Care Stocks Lower in Afternoon Trading

MT Newswires Live
·
07 May

Beam Therapeutics Shares Fall After Q1 Net Loss Widens

MT Newswires Live
·
06 May

Beam Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
06 May

Earnings Flash (BEAM) Beam Therapeutics Posts Q1 License and Collaboration Revenue $7.5M

MT Newswires Live
·
06 May

Earnings Flash (BEAM) Beam Therapeutics Posts Q1 Loss $1.24, vs. FactSet Est of -$1.18

MT Newswires Live
·
06 May

Beam Therapeutics Inc: Cash Runway Expected to Support Operating Plans Into 2028

THOMSON REUTERS
·
06 May

Beam Therapeutics Inc: Ended Q1 With $1.2 Bln in Cash, Cash Equivalents and Marketable Securities

THOMSON REUTERS
·
06 May

Beam Therapeutics Q1 License and Collaboration Revenue USD 7.47 Million

THOMSON REUTERS
·
06 May

Medical AI Stocks Soared. HIMS up 7%; Tempus up 6%; RXRX up 4%; Ginkgo up 3%.

Tiger Newspress
·
02 May

Beam Therapeutics Inc.'s (NASDAQ:BEAM) recent 11% pullback adds to one-year year losses, institutional owners may take drastic measures

Simply Wall St.
·
11 Apr

AI Biotech Stocks Shined. Recursion Soared 20% And Absci Surged 13%

Tiger Newspress
·
11 Apr

Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last?

Zacks
·
10 Apr

Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease

Benzinga
·
07 Apr

Beam Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Apr